Product Description: Camonsertib (RP-3500) is an orally active, selective ATR kinase inhibitor (ATRi) with an IC50 of 1.00 nM in biochemical assays. Camonsertib shows 30-fold selectivity for ATR over mTOR (IC50=120 nM) and >2,000-fold selectivity over ATM, DNA-PK, and PI3Kα kinases. Camonsertib has potent antitumor activity[1].
Applications: Cancer-Kinase/protease
Formula: C21H26N6O3
References: [1]Anne Roulston, et al. RP-3500: A Novel, Potent and Selective ATR Inhibitor that is Effective in Preclinical Models as a Monotherapy and in Combination with PARP Inhibitors. Mol Cancer Ther
CAS Number: 2417489-10-0
Molecular Weight: 410.47
Compound Purity: 99.75
Research Area: Cancer
Solubility: DMSO : 50 mg/mL (ultrasonic)
Target: ATM/ATR;mTOR